Patents by Inventor Hans Christian Wulf
Hans Christian Wulf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11730814Abstract: The present invention is related to a pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin.Type: GrantFiled: December 15, 2020Date of Patent: August 22, 2023Assignee: GALDERMA RESEARCH & DEVELOPMENTInventors: Hans Christian Wulf, Gloria Sanclemente
-
Publication number: 20210138068Abstract: The present invention is related to a pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin.Type: ApplicationFiled: December 15, 2020Publication date: May 13, 2021Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Hans Christian WULF, Gloria SANCLEMENTE
-
Patent number: 10953094Abstract: The present invention is related to a pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin.Type: GrantFiled: June 8, 2020Date of Patent: March 23, 2021Assignee: Galderma Research & DevelopmentInventors: Hans Christian Wulf, Gloria Sanclemente
-
Publication number: 20200323983Abstract: The present invention is related to a pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin.Type: ApplicationFiled: June 8, 2020Publication date: October 15, 2020Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Hans Christian WULF, Gloria SANCLEMENTE
-
Patent number: 10716855Abstract: A pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin is described.Type: GrantFiled: December 5, 2014Date of Patent: July 21, 2020Assignee: GALDERMA RESEARCH & DEVELOPMENTInventors: Hans Christian Wulf, Gloria Sanclemente
-
Patent number: 10543272Abstract: The invention provides the use of a photosensitiser which is a derivative (e.g. an ester) of 5-aminolevulinic acid (5-ALA), or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2 (e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight.Type: GrantFiled: October 2, 2015Date of Patent: January 28, 2020Assignee: PHOTOCURE ASAInventors: Hans Christian Wulf, Aslak Godal, Jo Klaveness, Per Harald Fuglerud
-
Publication number: 20190209686Abstract: A pulse photodynamic therapy (or pulse PDT) treatment of acne is described herein.Type: ApplicationFiled: January 2, 2019Publication date: July 11, 2019Applicant: GALDERMA RESEARCH & DEVELOPMENTInventor: Hans Christian WULF
-
Publication number: 20190125699Abstract: The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta2 adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta2 adrenoceptor agonist.Type: ApplicationFiled: December 21, 2018Publication date: May 2, 2019Applicant: CIPHER PHARMACEUTICALS INC.Inventors: Morten Sloth WEIDNER, Hans Christian WULF
-
Patent number: 9907765Abstract: The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta2 adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta2 adrenoceptor agonist.Type: GrantFiled: February 23, 2017Date of Patent: March 6, 2018Assignee: Cipher Pharmaceuticals Inc.Inventors: Morten Sloth Weidner, Hans Christian Wulf
-
Publication number: 20170157068Abstract: The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta2 adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta2 adrenoceptor agonist.Type: ApplicationFiled: February 23, 2017Publication date: June 8, 2017Inventors: Morten Sloth WEIDNER, Hans Christian WULF
-
Publication number: 20160346392Abstract: A pulse photodynamic therapy (or pulse PDT) treatment of skin complaints is described herein. The skin complaint being treated can be actinic keratosis (AK) or a basal cell carcinoma (BCC).Type: ApplicationFiled: December 19, 2014Publication date: December 1, 2016Inventor: Hans Christian WULF
-
Publication number: 20160339222Abstract: A pulse photodynamic therapy (or pulse PDT) treatment of acne is described herein.Type: ApplicationFiled: December 19, 2014Publication date: November 24, 2016Applicant: GALDERMA RESEARCH & DEVELOPMENTInventor: Hans Christian WULF
-
Publication number: 20160287701Abstract: A pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin is described.Type: ApplicationFiled: December 5, 2014Publication date: October 6, 2016Inventors: Hans Christian WULF, Gloria SANCLEMENTE
-
Publication number: 20160030565Abstract: The invention provides the use of a photosensitiser which is a derivative (e.g. an ester) of 5-aminolevulinic acid (5-ALA), or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2 (e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight.Type: ApplicationFiled: October 2, 2015Publication date: February 4, 2016Inventors: Hans Christian Wulf, Aslak Godal, Jo Klaveness, Per Harald Fuglerud
-
Publication number: 20150150972Abstract: The invention provides the use of a photosensitiser which is a derivative (e.g. an ester) of 5-aminolevulinic acid (5-ALA), or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2 (e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight.Type: ApplicationFiled: February 6, 2015Publication date: June 4, 2015Inventors: Hans Christian Wulf, Aslak Godal, Jo Klaveness, Per Harald Fuglerud
-
Patent number: 8759396Abstract: The invention provides the use of a photosensitizer which is 5-aminolevulinic acid (5-ALA) or a derivative (e.g. an ester) of 5-ALA, or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitizer; and (b) photoactivating said photosensitizer, and wherein side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitizer in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2 (e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight.Type: GrantFiled: January 11, 2008Date of Patent: June 24, 2014Assignee: Photocure ASAInventors: Hans Christian Wulf, Aslak Godal, Jo Klaveness
-
Publication number: 20130237607Abstract: The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta2 adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta2 adrenoceptor agonist.Type: ApplicationFiled: April 22, 2013Publication date: September 12, 2013Applicant: Astion Development A/SInventors: Morten Sloth WEIDNER, Hans Christian Wulf
-
Patent number: 8426475Abstract: The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta2 adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta2 adrenoceptor agonist.Type: GrantFiled: April 12, 2006Date of Patent: April 23, 2013Assignee: Astion Development A/SInventors: Morten Sloth Weidner, Hans Christian Wulf
-
Publication number: 20100137439Abstract: The invention provides the use of a photosensitiser which is 5-aminolevulinic acid (5-ALA) or a derivative (e.g. an ester) of 5-ALA, or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and wherein side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2 (e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight.Type: ApplicationFiled: January 11, 2008Publication date: June 3, 2010Inventors: Hans Christian Wulf, Aslak Godal, Jo Klaveness